Michael D. Laufert

No más puestos en curso

Consumer Services

Health Technology

Perfil

Mr. Laufert was previously employed as a Principal by GCP Fund III Corp., a Principal by Guilford Pharmaceuticals, Inc., and a Principal by Pfizer Inc. Mr. Laufert received his undergraduate degree from Mount St. Mary's College, a graduate degree from Georgetown University, and an MBA from Johns Hopkins University.

Antiguos cargos conocidos de Michael D. Laufert.

Empresas	Cargo	Fin
Guilford Pharmaceuticals, Inc. Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury	Corporate Officer/Principal	-
GCP Fund III Corp.	Corporate Officer/Principal	-
PFIZER, INC.	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Michael D. Laufert.

Formación de Michael D. Laufert.

The Johns Hopkins University	Masters Business Admin
Mount Saint Mary's University	Undergraduate Degree
Georgetown University	Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Michael D. Laufert.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
PFIZER, INC.	Health Technology

Empresas privadas	2
Guilford Pharmaceuticals, Inc. Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury	Health Technology
GCP Fund III Corp.